All News

Lknee.OA_.jpg

Meloxicam Superior to Placebo and Cognitive Behavioral Therapy in Knee OA

Jack Cush, MD

Pain management in knee osteoarthritis (OA) is confounded by studies showing less is equal to usual standards of care. A recent trial showed that meloxicam was superior to placebo or cognitive behavioral therap (CBT); although the differences were small. 

Read Article
T%20cell.jpg

PRIME Cells Predicting Rheumatoid Arthritis Flares

Jack Cush, MD

The current issue of NEJM reports a novel cell type that may be used to identify rheumatoid arthritis (RA) patients who may flare. 

Investigators prospectively collected blood samples from 4 patients for longitudinal RNA sequencing (RNA-seq) for discovery of moleculartranscripts that were differentially expressed before flares.

Read Article
RA9003.jpg (keep)

JAK Inhibitor Succeeds as Monotherapy in Rheumatoid Arthritis

RheumNow

The oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) given as monotherapy was more effective than methotrexate alone in methotrexate-naive patients with active rheumatoid arthritis (RA) in a multinational phase III trial.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

ICYMI: The Nine Lives of Hydroxychloroquine (Updated)

Martin J. Bergman, MD

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory arthropathy.

Read Article
45 yr adult male w/ Kawasaki-like multisystem inflammatory syndrome w/ COVID-19 infx: presented w/ 6d fever, sore throat, diarrhea, LN, BLE pain, conjunctivitis, tachycardia, ESR 120, CRP 546 mg/L, high Troponin; Rx and resolved w/ IVIG & TCZ https://t.co/cyRBJccKop

Links:

Dr. John Cush RheumNow ( View Tweet)

Genotyping and microbiota data TwinsUK study (excluding RA) shows that Prevotella spp were positively assoc with RA risk; further validated by first-degree relatives of RA patients where Prevotella was assoc w/ HLA-DRB1 & preclinical arthritis. https://t.co/7i2NNi7iip

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective study of 603 myositis (IIM), 4047 RA and 4061 controls shows IIM has higher risk of CV events (HR 1.38) and MI [HR 1.61] but not CVA [HR 0.92]. The CV risk in IIM was equal to that in RA [HR 1.01]. IIM CV risk only present 1st 5 years https://t.co/EyD3GHv2YY

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic review of DYSPHAGIA in inflammatory myositis finds it may be an initial or sole symptom. Prevalence in IIM was 36% and higher 56% inclusion body myositis, cancer or NXP2 -associated myositis. Dysphagia may be complicated by aspiration pneumonia https://t.co/wDg3tWaooP

Links:

Dr. John Cush RheumNow ( View Tweet)

The preliminary #ACR20 schedule is here! Along with all your favorite plenary and networking sessions, the program will feature #Rheumatologist Dr. Anthony Fauci giving us a live update on #COVID19. @ACRheum #ACRConvergence - Where Rheumatology Meets https://t.co/IWbiVw9PSP

Links:

Victoria Shanmugam VickiShanmugam ( View Tweet)

Italian report of 2 cases (1 w/ stable RA;1 without prior arthritis) who developed polyarthritis after hospitalization for COVID pneumonia. Synovial Bx showed synovial proliferation - 1 w/ crystals and both w/ CD3+ and CD138+ cells https://t.co/ZRRrWIjZXg

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatology reports a UK study of Clinical Practice Research Datalink and 17 760 incident RA pts; 42% who recv steroids; The HTN rate was 64.1 per 1000 PY & GC use assoc w/ 17% increased risk HTN (hazard ratio 1.17), esp at doses > 7.5 mg/d https://t.co/31Q2xiwvMp

Links:

Dr. John Cush RheumNow ( View Tweet)

Canadian 1484 incident early #RA pts (enrolled 2007–2017). SC MTX monotherapy had fewer Rx changes(45% SC vs 79% PO)with longer treatment duration. Similarly taking biologics or triple therapy had a longer time without treatment change. https://t.co/babj1MvTNB

Links:

Dr. John Cush RheumNow ( View Tweet)

NEW #COVID19—"Symmetric peripheral polyarthritis developed during #SARSCoV2 infection" Comment by Rosario Talarico and colleagues https://t.co/IqHp2GMLao #LancetRheumatology https://t.co/v3MBNDUnzG

Links:

The Lancet Rheumatology TheLancetRheum ( View Tweet)

FDA has approved a 6th adalimumab biosimilar - called Hulio (adalimumab-fkjp) with indications of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, psoriasis. https://t.co/zMNsDjVewU

Links:

Dr. John Cush RheumNow ( View Tweet)

Check my updated virtual video joint exam for rheumatologists - Video here> https://t.co/ZXEUKcw5mb or listen to the podcast>> https://t.co/XSHWuwxJ9L https://t.co/lBtG0lvAZM

Links:

Dr. John Cush RheumNow ( View Tweet)
H2H UPA vs ABA RCT; UPA is clinically superior to ABA in DAS-CRP remission, ACR50, ACR70 at wk 12/24 (NOT diff in P… https://t.co/7lwVCSYjPu

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush. Watch it on RheumNow https://t.co/5v9BTuLrPX or listen to the podcast on iTunes https://t.co/FHJv01AAbC or on Android Sound Cloud https://t.co/nb7iXdRMMb

Links:

Dr. John Cush RheumNow ( View Tweet)

Case Controlled Study of 482 RA patients with ILD vs 741 RA w/o IL found an inverse relationship Between MTX exposu… https://t.co/ljtaKO8pVZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatologist Question: early on, what do you tell your RA patient their chance of future drug free remission?

Dr. John Cush RheumNow ( View Tweet)

Rheumatoid Arthritis: Pathogenesis, Prediction and Prevention – An Emerging Paradigm Shift https://t.co/uNDsLmgaN7 #RA #prevention #Rituximab - nice article, still think if repeated Ritux to eliminate pathogenic abs would significantly prevent RA

Links:

Peter Nash drpnash ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×